

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奥赛图(北京)医药科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

INSIDE INFORMATION

THE PROGRESS OF PROPOSED ISSUE OF A SHARES

FINANCIAL INFORMATION IN RELATION TO A SHARE PROSPECTUS

This announcement is made by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements dated March 6, 2023, March 15, 2023, June 20, 2023, September 17, 2025, November 3, 2025 and November 19, 2025 and the circulars dated March 31, 2023 and November 3, 2025 of the Company containing, among other things, related matters of the proposed initial public issue of A shares and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. Unless otherwise defined, capitalized terms used in this announcement shall have the meanings as defined in the above announcements and circulars.

The Company has submitted a prospectus of initial public offer and listing on the SCI-Tech Board of the share (the “**A Share Prospectus**”) and related materials in connection with the Proposed Issue of A Shares on November 20, 2025. The A Share Prospectus and related materials have been published on the website of the Review and Approval of the Issuance and Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange (上交所科创板股票发行上市审核网站) at kcb.sse.com.cn.

The A Share Prospectus contains, among other things, consolidated financial information of the Company and its subsidiary for the nine months ended September 30, 2025 (the “**Consolidated Financial Information**”). The Consolidated Financial Information is prepared in accordance with Accounting Standards for Business Enterprises issued by the Ministry of Finance of the People’s Republic of China and has been reviewed by KPMG Huazhen LLP, the details of which are as follows:

	As at September 30, 2025 <i>RMB’000</i> (Unaudited)	As at December 31, 2024 <i>RMB’000</i> (Audited)	Changes <i>RMB’000</i> %	
Total assets	2,444,933.8	2,415,313.6	29,620.2	1.2
Total liabilities	1,464,625.0	1,576,709.8	(112,084.8)	(7.1)
Total equity	980,308.8	838,603.8	141,705.0	16.9
Total equity attributable to shareholders of the Company	975,764.0	834,058.8	141,705.2	17.0
	Nine months ended September 30, 2025 <i>RMB’000</i> (Unaudited)	2024 <i>RMB’000</i> (Unaudited)	Changes <i>RMB’000</i> %	
Operating income	940,881.3	589,882.3	350,999.0	59.5
Research and development expenses	313,050.7	239,730.0	73,320.7	30.6
Operating profit/(loss)	129,677.8	(93,785.7)	223,463.5	N/A
Profit/(Loss) before income tax	129,078.7	(95,205.8)	224,284.5	N/A
Net profit/(loss) for the period	114,126.5	(102,272.0)	216,398.5	N/A
Profit/(Loss) attributable to shareholders of the Company	114,126.9	(102,270.6)	216,397.5	N/A
Net cash inflow from operating activities	262,770.7	100,203.2	162,567.5	162.2
Net cash outflow from investing activities	(185,006.4)	(139,459.6)	(45,546.8)	32.7
Net cash outflow from financing activities	(143,300.8)	(67,949.3)	(75,351.5)	110.9
Net decrease in cash and cash equivalents	(63,910.0)	(107,108.4)	43,198.4	(40.3)

The above English version of the summary of the Consolidated Financial Information is an unofficial translation of its Chinese version. In case of any discrepancies, the Chinese version shall prevail.

As the Proposed Issue of A Shares is subject to certain conditions precedent, it may or may not be completed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the H shares of the Company. Further announcement(s) regarding the details and developments of the Proposed Issue of A Shares will be made by the Company as and when appropriate. This announcement appears for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for the securities of the Company.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelel
*Chairman of the Board, Chief Executive Officer and
Executive Director*

Hong Kong, 20 November, 2025

As at the date of this announcement, the Board comprises Dr. Shen Yuelel as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.